AR011607A1 - Polipeptido aislado que codifica un supresor tumoral ts10q23.3, anticuerpo monoclonal , celula de hibridoma, antisuero policlonal, acido nucleico yoligonucleotido aislados. metodo para diagnosticar cancer, alterar el fenotipo de una celula tumoral, determinar el estadio de un cancer, pronosticar - Google Patents

Polipeptido aislado que codifica un supresor tumoral ts10q23.3, anticuerpo monoclonal , celula de hibridoma, antisuero policlonal, acido nucleico yoligonucleotido aislados. metodo para diagnosticar cancer, alterar el fenotipo de una celula tumoral, determinar el estadio de un cancer, pronosticar

Info

Publication number
AR011607A1
AR011607A1 ARP980100442A ARP980100442A AR011607A1 AR 011607 A1 AR011607 A1 AR 011607A1 AR P980100442 A ARP980100442 A AR P980100442A AR P980100442 A ARP980100442 A AR P980100442A AR 011607 A1 AR011607 A1 AR 011607A1
Authority
AR
Argentina
Prior art keywords
cancer
tumor suppressor
gene
tumor
isolated
Prior art date
Application number
ARP980100442A
Other languages
English (en)
Original Assignee
Univ Texas
Myriad Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25152739&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR011607(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Texas, Myriad Genetics Inc filed Critical Univ Texas
Publication of AR011607A1 publication Critical patent/AR011607A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Se ha encontrado que una region del cromosoma 10 (10q23.3), mediante una serie de estudios, contiene un gen supresor de tumores involucrado en losgliomas, así como en una cantidad de cánceres distintos de seres humanos. Se identifico un gen dentro de esta region y la correspondiente region decodificacion del gen representa una nueva proteína de 47 kD. Un dominio de este producto coincide exactamente con el dominio catalítico conservado de lasproteínas tirosina fosfatasas, lo cual sugiere un posible rol funcional en los sucesos de fosforilacion. Los análisis de secuencia demostraron que sesuprimía una cantidad de exones del gen en las líneas de células tumorales utilizadas para definir la region 10q23.3, lo cual lleva a clasificar estegen como un supresor de tumores. Otros análisis han demostrado la presencia de una cantidad de mutaciones en el gen, tanto de células de glioma como decarcinoma de prostata. También se describen los métodos para diagnosticar y tratarlos cánceres relacionados con este supresor de tumores, denominadoTS10q23.3.
ARP980100442A 1997-01-30 1998-01-30 Polipeptido aislado que codifica un supresor tumoral ts10q23.3, anticuerpo monoclonal , celula de hibridoma, antisuero policlonal, acido nucleico yoligonucleotido aislados. metodo para diagnosticar cancer, alterar el fenotipo de una celula tumoral, determinar el estadio de un cancer, pronosticar AR011607A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/791,115 US6262242B1 (en) 1997-01-30 1997-01-30 Tumor suppressor designated TS10Q23.3

Publications (1)

Publication Number Publication Date
AR011607A1 true AR011607A1 (es) 2000-08-30

Family

ID=25152739

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980100442A AR011607A1 (es) 1997-01-30 1998-01-30 Polipeptido aislado que codifica un supresor tumoral ts10q23.3, anticuerpo monoclonal , celula de hibridoma, antisuero policlonal, acido nucleico yoligonucleotido aislados. metodo para diagnosticar cancer, alterar el fenotipo de una celula tumoral, determinar el estadio de un cancer, pronosticar

Country Status (14)

Country Link
US (1) US6262242B1 (es)
EP (2) EP2366712A3 (es)
JP (5) JP2001511002A (es)
AR (1) AR011607A1 (es)
AT (1) ATE499444T1 (es)
AU (1) AU745296B2 (es)
CA (1) CA2278849C (es)
DE (1) DE69842141D1 (es)
DK (1) DK0972024T4 (es)
ES (1) ES2361044T5 (es)
IL (1) IL131168A0 (es)
PT (1) PT972024E (es)
WO (1) WO1998033907A1 (es)
ZA (1) ZA98756B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287854B1 (en) 1996-10-22 2001-09-11 Imperial Cancer Research Technology Limited Diagnosis of susceptibility to cancer and treatment thereof
US6482795B1 (en) 1997-01-30 2002-11-19 Myriad Genetics, Inc. Tumor suppressor designated TS10q23.3
EP1023076A4 (en) * 1997-02-07 2001-11-21 Univ Columbia USE OF THE P-TEN TUMOR SUPPRESSOR GENE IN THE DIAGNOSIS AND TREATMENT OF CANCER
US6225120B1 (en) 1997-05-15 2001-05-01 The General Hospital Corporation Therapeutic and diagnostic tools for impaired glucose tolerance conditions
US6861256B2 (en) 1997-05-15 2005-03-01 The General Hospital Corporation Therapeutic and diagnostic tools for impaired glucose tolerance conditions
WO1999002704A2 (en) * 1997-07-08 1999-01-21 Cold Spring Harbor Laboratory Dual specifically phosphatase and methods of use
DE69830596T2 (de) * 1997-08-26 2006-03-16 Board of Regents, The University of Texas System, Austin Ein tumorsuppressor namens ts10q23.3
AU2002226028A1 (en) 2000-11-14 2002-05-27 Board Of Regents, Unversity Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
CA2470088A1 (en) * 2001-12-20 2003-07-03 Tularik Inc. Identification of an amplified gene and target for drug intervention
EP1756137A4 (en) * 2003-11-05 2007-10-31 Univ Texas DIAGNOSTIC AND THERAPEUTIC PROCEDURES AND COMPOSITIONS CONCERNING PTEN AND BREAST CANCER
CN103424541B (zh) 2006-05-18 2018-01-30 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
US8583380B2 (en) 2008-09-05 2013-11-12 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
CN102301002A (zh) * 2008-11-12 2011-12-28 卡里斯生命科学卢森堡控股有限责任公司 使用外来体来确定表现型的方法和系统
JP5808349B2 (ja) 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー セラノーシスのためのバイオマーカー
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
EP2619329B1 (en) 2010-09-24 2019-05-22 The Board of Trustees of The Leland Stanford Junior University Direct capture, amplification and sequencing of target dna using immobilized primers
CN110055325A (zh) 2011-12-30 2019-07-26 雅培分子公司 用于前列腺癌的诊断、预后和评估治疗性/预防性治疗的材料和方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4883750A (en) 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
AU622104B2 (en) 1987-03-11 1992-04-02 Sangtec Molecular Diagnostics Ab Method of assaying of nucleic acids, a reagent combination and kit therefore
FR2616841A1 (fr) 1987-06-17 1988-12-23 Rauner Hans Perfectionnements au systeme de bloquage en position ouverte a levier de serrage pivotant, pour fiches et paumelles de portes et de fenetres
IL86724A (en) 1987-06-19 1995-01-24 Siska Diagnostics Inc Methods and kits for amplification and testing of nucleic acid sequences
AU622426B2 (en) 1987-12-11 1992-04-09 Abbott Laboratories Assay using template-dependent nucleic acid probe reorganization
DE68908054T2 (de) 1988-01-21 1994-03-10 Genentech Inc Verstärkung und nachweis von nukleinsäuresequenzen.
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US4932207A (en) 1988-12-28 1990-06-12 Sundstrand Corporation Segmented seal plate for a turbine engine
US5279721A (en) 1993-04-22 1994-01-18 Peter Schmid Apparatus and method for an automated electrophoresis system
CN1203633A (zh) 1995-10-23 1998-12-30 帝国癌症研究技术有限公司 对癌症的易感性诊断及其治疗
DE69830596T2 (de) * 1997-08-26 2006-03-16 Board of Regents, The University of Texas System, Austin Ein tumorsuppressor namens ts10q23.3
US8312249B1 (en) 2008-10-10 2012-11-13 Apple Inc. Dynamic trampoline and structured code generation in a signed code environment
FR2957821B1 (fr) 2010-03-24 2014-08-29 Inst Francais Du Petrole Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives

Also Published As

Publication number Publication date
PT972024E (pt) 2011-05-05
JP2010259438A (ja) 2010-11-18
EP0972024B1 (en) 2011-02-23
JP4768783B2 (ja) 2011-09-07
ES2361044T3 (es) 2011-06-13
ES2361044T5 (es) 2014-10-01
DK0972024T4 (da) 2014-07-07
EP2366712A2 (en) 2011-09-21
JP2013128485A (ja) 2013-07-04
IL131168A0 (en) 2001-01-28
DE69842141D1 (de) 2011-04-07
JP2001511002A (ja) 2001-08-07
AU6018998A (en) 1998-08-25
EP0972024A1 (en) 2000-01-19
DK0972024T3 (da) 2011-04-26
CA2278849A1 (en) 1998-08-06
AU745296B2 (en) 2002-03-21
WO1998033907A1 (en) 1998-08-06
JP5202583B2 (ja) 2013-06-05
EP0972024B2 (en) 2014-06-25
ZA98756B (en) 1998-08-25
CA2278849C (en) 2016-04-19
US6262242B1 (en) 2001-07-17
JP2009039107A (ja) 2009-02-26
JP2014155493A (ja) 2014-08-28
ATE499444T1 (de) 2011-03-15
EP2366712A3 (en) 2012-11-14

Similar Documents

Publication Publication Date Title
AR011607A1 (es) Polipeptido aislado que codifica un supresor tumoral ts10q23.3, anticuerpo monoclonal , celula de hibridoma, antisuero policlonal, acido nucleico yoligonucleotido aislados. metodo para diagnosticar cancer, alterar el fenotipo de una celula tumoral, determinar el estadio de un cancer, pronosticar
GJG et al. Tumor-educated platelets
Türeci et al. Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens
Soteriou et al. A survey of interactions made by the giant protein titin
Hoek et al. hnRNP A2 selectively binds the cytoplasmic transport sequence of myelin basic protein mRNA
Petrović et al. The prognostic significance of the circulating neuroendocrine markers chromogranin A, pro-gastrin-releasing peptide, and neuron-specific enolase in patients with small-cell lung cancer
McMahon et al. Human α spectrin II and the Fanconi anemia proteins FANCA and FANCC interact to form a nuclear complex
Solomonov et al. Distinct biological events generated by ECM proteolysis by two homologous collagenases
DK1295944T3 (da) GDP-dissociationsstimulerende protein, hjernespecifikt nukleosomsamlingsprotein, skeletmuskelspecifikt ubiquitinkonjugerende enzym, celleproliferationsprotein, phosphatidylinositolkinase, nelbeslægtede proteiner
Lux et al. Circular RNAs in cancer
AR017562A1 (es) UN ANTIGENO POLIPEPTIDICO ESPECIFICO DE TUMORES, SU USO, UN METODO PARA PRODUCIRLO, METODOS PARA EL AISLAMIENTO DE mRNA DE UN ANTIGENO ESPECIFICO DETUMORES Y PARA LA MEDICION DE LA PROLIFERACION DE CELULAS T CITOTOXICAS ESPECIFICAS DE TUMORES Y USO DE UN ACIDO NUCLEICO CODIFICADOR DE UN ANTIGENOPOLI
DE69834824D1 (de) Nukleinsäure, welche einen von lektin abstammenden faktor zur präservierung von progenitorzellen kodiert
Regnard et al. Characterisation of PGs1, a subunit of a protein complex co-purifying with tubulin polyglutamylase
Xu et al. 14-kDa phosphohistidine phosphatase and its role in human lung cancer cell migration and invasion
Parrish et al. Size heterogeneity, phosphorylation and transmembrane organisation of desmosomal glycoproteins 2 and 3 (desmocollins) in MDCK cells
Sakai et al. Novel RUNX1‐PRDM16 fusion transcripts in a patient with acute myeloid leukemia showing t (1; 21)(p36; q22)
Keon et al. Isoform specific expression of the neuronal F-actin binding protein, drebrin, in specialized cells of stomach and kidney epithelia
Yoon et al. NOTUM is involved in the progression of colorectal cancer
Teshima et al. Comparison of properties of stem cells isolated from adipose tissue and lipomas in dogs
Teye et al. Isolation of all CD44 transcripts in human epidermis and regulation of their expression by various agents
ATE298003T1 (de) Ein tumorsuppressor namens ts10q23.3
UY24389A1 (es) Composición farmacéutica para el tratamiento de carcinoma de epitelio plano
Deng et al. iTRAQ-based quantitative proteomic analysis of esophageal squamous cell carcinoma
Kuo et al. Characterization of EHD4, an EH domain-containing protein expressed in the extracellular matrix
Du et al. P leckstrin‐2‐promoted PPM1B degradation plays an important role in transforming growth factor‐β‐induced breast cancer cell invasion and metastasis

Legal Events

Date Code Title Description
FA Abandonment or withdrawal